Clinical Trial Update: Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ranibizumab 0.5 mg to verteporfin PDT for visual impairment from CNV due to pathologic myopia; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

Drugs mentioned

• ranibizumab 0.5 mg (ranibizumab)
• verteporfin PDT (verteporfin photodynamic therapy)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM) | Phase 3 | Status: COMPLETED | Results posted: 2019-06-24